350 related articles for article (PubMed ID: 17542770)
1. Pharmacogenetics of beta-blockers.
Shin J; Johnson JA
Pharmacotherapy; 2007 Jun; 27(6):874-87. PubMed ID: 17542770
[TBL] [Abstract][Full Text] [Related]
2. Beta-blocker pharmacogenetics in heart failure.
Shin J; Johnson JA
Heart Fail Rev; 2010 May; 15(3):187-96. PubMed ID: 18437562
[TBL] [Abstract][Full Text] [Related]
3. The pharmacogenetics of β-adrenergic receptor antagonists in the treatment of hypertension and heart failure.
Chan SW; Hu M; Tomlinson B
Expert Opin Drug Metab Toxicol; 2012 Jul; 8(7):767-90. PubMed ID: 22621216
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenetic factors affecting β-blocker metabolism and response.
Thomas CD; Johnson JA
Expert Opin Drug Metab Toxicol; 2020 Oct; 16(10):953-964. PubMed ID: 32726152
[TBL] [Abstract][Full Text] [Related]
5. Clinical application of cardiovascular pharmacogenetics.
Voora D; Ginsburg GS
J Am Coll Cardiol; 2012 Jul; 60(1):9-20. PubMed ID: 22742397
[TBL] [Abstract][Full Text] [Related]
6. Carvedilol pharmacokinetics and pharmacodynamics in relation to CYP2D6 and ADRB pharmacogenetics.
Sehrt D; Meineke I; Tzvetkov M; Gültepe S; Brockmöller J
Pharmacogenomics; 2011 Jun; 12(6):783-95. PubMed ID: 21599570
[TBL] [Abstract][Full Text] [Related]
7. Genetic variation in the CYP2D6 gene is associated with a lower heart rate and blood pressure in beta-blocker users.
Bijl MJ; Visser LE; van Schaik RH; Kors JA; Witteman JC; Hofman A; Vulto AG; van Gelder T; Stricker BH
Clin Pharmacol Ther; 2009 Jan; 85(1):45-50. PubMed ID: 18784654
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenomics of heart failure: a systematic review.
Mottet F; Vardeny O; de Denus S
Pharmacogenomics; 2016 Nov; 17(16):1817-1858. PubMed ID: 27813451
[TBL] [Abstract][Full Text] [Related]
9. Chronic heart failure: beta-blockers and pharmacogenetics.
Azuma J; Nonen S
Eur J Clin Pharmacol; 2009 Jan; 65(1):3-17. PubMed ID: 18839161
[TBL] [Abstract][Full Text] [Related]
10. Associations between ADRB1 and CYP2D6 gene polymorphisms and the response to β-blocker therapy in hypertension.
Wu D; Li G; Deng M; Song W; Huang X; Guo X; Wu Z; Wu S; Xu J
J Int Med Res; 2015 Jun; 43(3):424-34. PubMed ID: 25823457
[TBL] [Abstract][Full Text] [Related]
11. Pharmacogenetics of beta1-adrenergic receptors in heart failure and hypertension.
Mialet-Perez J; Liggett SB
Arch Mal Coeur Vaiss; 2006 Jun; 99(6):616-20. PubMed ID: 16878723
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic relevance of pharmacogenetic factors in cardiovascular medicine.
Nakagawa K; Ishizaki T
Pharmacol Ther; 2000 Apr; 86(1):1-28. PubMed ID: 10760544
[TBL] [Abstract][Full Text] [Related]
13. An evaluation of the beta-1 adrenergic receptor Arg389Gly polymorphism in individuals with heart failure: a MERIT-HF sub-study.
White HL; de Boer RA; Maqbool A; Greenwood D; van Veldhuisen DJ; Cuthbert R; Ball SG; Hall AS; Balmforth AJ;
Eur J Heart Fail; 2003 Aug; 5(4):463-8. PubMed ID: 12921807
[TBL] [Abstract][Full Text] [Related]
14. Genetic variation, β-blockers, and perioperative myocardial infarction.
Nagele P; Liggett SB
Anesthesiology; 2011 Dec; 115(6):1316-27. PubMed ID: 21918425
[TBL] [Abstract][Full Text] [Related]
15. β
Shahin MH; Rouby NE; Conrado DJ; Gonzalez D; Gong Y; Lobmeyer MT; Beitelshees AL; Boerwinkle E; Gums JG; Chapman A; Turner ST; Pepine CJ; Cooper-DeHoff RM; Johnson JA
J Clin Pharmacol; 2019 Nov; 59(11):1462-1470. PubMed ID: 31090079
[TBL] [Abstract][Full Text] [Related]
16. Pharmacogenetic polymorphisms affecting bisoprolol response.
Castaño-Amores C; Díaz-Villamarín X; Pérez-Gutiérrez AM; Antúnez-Rodríguez A; Pozo-Agundo A; Moreno-Escobar E; Sánchez-Ramos JG; Martínez-González LJ; Dávila-Fajardo CL
Biomed Pharmacother; 2021 Oct; 142():112069. PubMed ID: 34470728
[TBL] [Abstract][Full Text] [Related]
17. Frequency of genetic polymorphism for adrenergic receptor beta and cytochrome p450 2D6 enzyme, and effects on tolerability of beta-blocker therapy in heart failure with reduced ejection fraction patients: The Beta GenTURK study.
Zoghi M; Kaya H; Çavuşoğlu Y; Aksakal E; Demir Ş; Yücel C; Mutlu H; Ergene O; Yılmaz MB;
Turk Kardiyol Dern Ars; 2016 Sep; 44(6):457-65. PubMed ID: 27665326
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenetic Associations of β1-Adrenergic Receptor Polymorphisms With Cardiovascular Outcomes in the SPS3 Trial (Secondary Prevention of Small Subcortical Strokes).
Magvanjav O; McDonough CW; Gong Y; McClure LA; Talbert RL; Horenstein RB; Shuldiner AR; Benavente OR; Mitchell BD; Johnson JA;
Stroke; 2017 May; 48(5):1337-1343. PubMed ID: 28351962
[TBL] [Abstract][Full Text] [Related]
19. Pharmacogenetics of antihypertensive treatment.
Arnett DK; Claas SA; Glasser SP
Vascul Pharmacol; 2006 Feb; 44(2):107-18. PubMed ID: 16356784
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenetic profiling in the treatment of heart disease.
Dorn GW
Transl Res; 2009 Dec; 154(6):295-302. PubMed ID: 19931195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
